Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.

Official Title

Esprit BTK Post-Approval Study (Esprit BTK PAS)

Keywords

Chronic Limb-Threatening Ischemia, ABT-CIP-10519, Esprit BTK System, Infrapopliteal lesions, Post-approval study

Eligibility

You can join if…

Open to people ages 18 years and up

  • General Inclusion Criteria
    1. Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
      1. Informed consent can be obtained up to 3 days post-procedure or prior to discharge whichever comes first.
      2. Subject, or a legally acceptable representative must provide written informed consent per site IRB/EC requirements.
    2. Subject must be at least 18 years of age.
    3. Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions.
  • Anatomic Inclusion Criteria
    1. Subjects who have lesion(s) in an infrapopliteal vessel with reference vessel diameter ≥ 2.5 mm and ≤ 4.0 mm.
    2. Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography and intravascular imaging) can be used to aid accurate sizing of the vessels.

You CAN'T join if...

  • General Exclusion Criteria
    1. Subjects who have contraindications to the Esprit BTK System per the instruction for use (IFU).
    2. Subject is currently participating in another clinical investigation.
    3. Subject is unable or unwilling to provide written consent prior to enrollment.
    4. Subject with life expectancy ≤ 1 year.
    5. Subject with an unsalvageable limb (as per physician assessment at the time of the index procedure), who is likely to get a below-the-knee amputation.
  • Anatomic Exclusion Criteria
    1. Subject has in-stent restenosis in the target vessel or requires treatment with a metallic stent in the target vessel during the index procedure.
    2. Subject had been previously treated with Esprit BTK Scaffold(s).

Locations

  • Ronald Reagan UCLA Medical Center not yet accepting patients
    Los Angeles California 90095 United States
  • Good Samaritan Hospital not yet accepting patients
    Los Angeles California 90017 United States
  • Hendrick Medical Center accepting new patients
    Abilene Texas 79601 United States
  • Hightower Clinical accepting new patients
    Oklahoma City Oklahoma 73102 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Abbott Medical Devices
ID
NCT06656364
Study Type
Interventional
Participants
Expecting 200 study participants
Last Updated